Navigation Links
Stem cell therapy shows promise in regenerating damaged muscle in heart attack patients

ent, it is believed that they do not trigger an immune response when placed in someone else's body.

Similar to Blood Type O, these MSCs are being used without tissue type matching to a specific patient.

A unique benefit of the stem cell product is that it is given to patients through a standard IV line. Other therapies require delivery to the site of the disease through catheterization or open surgical procedures, but this one was very simple and easy for the patient.

Schaer says the cells were grown in culture to very high numbers, allowing a single donor's cells to treat thousands of patients. "The cells have the ability to expand, or multiply, under controlled conditions, and the expanded cells have the ability to develop into different types of cells in the appropriate environment. One donation can produce billions of MSCs. The cells can be stored for years in a frozen state, ready to be used when they are needed."

Adult stem cells are designed by nature to perform tissue repair in a mature adult. It is believed that these cells can be used in patients unrelated to the donor, without rejection, eliminating the need for donor matching and recipient immune suppression. Once transplanted, the cells promote healing of damaged or diseased tissues.

"Because of the participation by top tier sites such as Rush University Medical Center, we were able to conduct a study that was exceptionally well planned and executed" said C. Randal Mills Ph.D., President and CEO of Osiris Therapeutics. "We were confident in the safety profile given our previous experience using the intravenous form of these stem cells to treat other diseases in later stage clinical trials. However, we did not expect to see the across-the-board clinical improvement observed in patients at this early stage of testing."


'"/>

Source:Rush University Medical Center


Page: 1 2

Related biology news :

1. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
2. Columbia research lifts major hurdle to gene therapy for cancer
3. Combination therapy boosts effectiveness of telomere-directed cancer cell death
4. Gene therapy converts dead bone graft to new, living tissue
5. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
6. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
7. Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
8. New therapy for HIV/AIDS eliminates needles and excessive toxicity
9. New Treatment Rivals Chemotherapy For Lymphoma, Study Finds
10. Gene therapy for Parkinsons disease moves forward in animals
11. Pulsating ultrasound enhances gene therapy for tumors
Post Your Comments:
(Date:8/11/2015)... GOTHENBURG, Sweden , August 11, 2015 ... sensor FPC1155. Already received as well as expected revenues in 2015 ... included in FPC,s communicated revenue guidance of approximately 2,200 MSEK for ... is a prominent smartphone manufacturer ... ZUK selected FPC1 155 ...
(Date:8/6/2015)... CITY, Calif. , Aug. 6, 2015 /PRNewswire/ ... Valley) will visit Crossmatch ™ to learn ... networks and protect data. Crossmatch is a world ... whose technologies and expertise are helping federal agencies ... efficiency and security.   "The vast ...
(Date:8/5/2015)... -- According to a new market research ... Vertical (BFSI, Airport, IT & Telecom, Utilities, Education, Defense ... 2020", published by MarketsandMarkets, defines and segments the Physical ... The global PIAM Market is estimated to grow from ... at a CAGR of 14.9 % from 2014 to ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Rep. Honda to Visit Crossmatch in Redwood City 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
... Health & Science University (OHSU) and Intel Corp. ... that advance the field of personalized medicine by ... analyzing a patient,s individual genetic profile. Through a ... and scientists from the two institutions will develop ...
... developers may have a new tool to search for more ... that can model and catalogue the entire set of lightweight, ... The small-molecule universe has more than 10^60 (that,s 1 ... Beratan said that many of the world,s problems have molecular ...
... Philosophical Transactions of The Royal Society Biological Sciences ... a global population that is simultaneously growing and increasing ... and social impoverishment. According to Michael T. ... (WHRC) and one of the issue,s co-editors, "One important ...
Cached Biology News:OHSU teams with Intel to decode the root causes of cancer and other complex diseases 2OHSU teams with Intel to decode the root causes of cancer and other complex diseases 3OHSU teams with Intel to decode the root causes of cancer and other complex diseases 4OHSU teams with Intel to decode the root causes of cancer and other complex diseases 5Scientists map all possible drug-like chemical compounds 2Scientists map all possible drug-like chemical compounds 3Ecology, economy and management of an agro-industrial Amazon frontier 2Ecology, economy and management of an agro-industrial Amazon frontier 3
(Date:8/26/2015)... , Aug. 26, 2015  Platform therapeutic ... it has received a $1.5M Phase II SBIR ... to further develop its therapeutic agent to reduce ... need in end stage renal disease (ESRD) patients ... National Institute of Diabetes and Digestive and Kidney ...
(Date:8/26/2015)... , August 26, 2015 Israel Proves Its ... wins 1 st place  Wayerz comes in 5 ... Israel by venture capital fund JVP, with Chinese ... US, China , Israel , ... .  Impressive achievement for the Israeli representatives in the ...
(Date:8/26/2015)... -- After litigating and negotiating patent infringement claims ... United States patent RE43,651 (the ,651 ... the United States without any admission or concession ... As a result of the parties, settlement, the US District ... dismissed the case without prejudice. Under the ...
(Date:8/26/2015)... ... August 26, 2015 , ... PRC Clinical, ... new business relationships with local sponsors in southern California. The Clinical Trial Management Expert ... development processes and regulatory pathways., , Stem Cell Meeting ...
Breaking Biology Technology:Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 5Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 6P2i Settles United States Litigation 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3
... Calif., Aug. 25, 2011 Emmy® and Tony® award-winning ... ) today launch Act 2 Reduce Fractures™, an educational ... for fractures. Earlier this year, Danner was diagnosed with ... to encourage women like her to educate themselves, take ...
... 25, 2011 SyntheMed, Inc. (OTC Bulletin Board: ... announced that its stockholders approved the planned merger with ... today.  In excess of 99% of the votes cast ... merger with Pathfinder was previously announced and is described ...
... Hikma Pharmaceuticals reports lower-than-expected 3.2% increase in revenues ... The international drug developer says that political ... some key countries like Egypt and Tunisia. ... Hikma CEO Said Darwazah says that production is back ...
Cached Biology Technology:Award-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures(TM) Educational Campaign 2Award-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures(TM) Educational Campaign 3Award-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures(TM) Educational Campaign 4Award-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures(TM) Educational Campaign 5Award-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures(TM) Educational Campaign 6Award-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures(TM) Educational Campaign 7SyntheMed, Inc. Announces Stockholder Approval of Planned Merger With Pathfinder, LLC 2SyntheMed, Inc. Announces Stockholder Approval of Planned Merger With Pathfinder, LLC 3
...
... a hydrolytic enzyme that catalyzes the ... glucose, maltose, maltotriose and,dextrins. The level ... the human,body are of clinical importance,1-3 ... enzymes for industry.4, The EnzChek Amylase ...
... The Jouan MSC series of ... comfortable working conditions and certification to ... automatic regulation ensures that the cabinets ... working conditions. Natural lighting, low noise ...
Rabbit polyclonal to STUB1 ( Abpromise for all tested applications). entrezGeneID: 10273 SwissProtID: Q9UNE7...
Biology Products: